Novartis Settles Patent Litigation Over Gleevec - - BioPharm International

ADVERTISEMENT

Novartis Settles Patent Litigation Over Gleevec



Novartis Pharmaceuticals has settled its litigation with the US subsidiary of Sun Pharmaceutical Industries, regarding patents covering the use of certain polymorphic forms of Gleevec (imatinib mesylate), which expire in 2019 (including pediatric exclusivity). The basic compound patent for Gleevec expires in the US on July 4, 2015.

As a result of the settlement, Novartis will permit Sun Pharma's subsidiary to market a generic version of Gleevec in the US on February 1, 2016. The terms of the settlement agreement are otherwise confidential. Sun Pharma's subsidiary has received tentative approval from FDA for its generic version of imatinib mesylate.

Source: Novartis Pharmaceuticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

J&J Speeds Ebola Vaccine Development and Expands Production
October 24, 2014
Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Manufacturing Challenges of mAb Production: CHO or Plant Cells?
October 24, 2014
Celgene and Sutro Partner on ADC Development
October 24, 2014
GSK Accelerates Ebola Vaccine Development
October 24, 2014
Author Guidelines

Click here